HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Cynomolgus
HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Cynomolgus

The purity of HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Cynomolgus is greater than 95% as determined by SEC-HPLC.

HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Cynomolgus

HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Cynomolgus

HLA-G is a molecule that was first known to confer protection to the fetus from destruction by the immune system of its mother, thus critically contributing to fetal-maternal tolerance. The first functional finding constituted the basis for HLA-G research and can be summarized as such: HLA-G, membrane-bound or soluble, strongly binds its inhibitory receptors on immune cells (NK, T, B, monocytes/dendritic cells), inhibits the functions of these effectors, and so induces immune inhibition.
Z06535
¥63,425.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
HLA-G&B2M&Peptide (RIIPRHLQL) Monomer [Gly25-Thr305(HLA-G), Ile21-Met119(B2M) and RIIPRHLQL peptide]
Accession # E0WKX9(HLA-G)&Q8SPW0(B2M)&RIIPRHLQL		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 50.6 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Cynomolgus
    • HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Cynomolgus

    The purity of HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Cynomolgus is greater than 95% as determined by SEC-HPLC.

  • HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Cynomolgus
    • HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Cynomolgus

    HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background HLA-G is a molecule that was first known to confer protection to the fetus from destruction by the immune system of its mother, thus critically contributing to fetal-maternal tolerance. The first functional finding constituted the basis for HLA-G research and can be summarized as such: HLA-G, membrane-bound or soluble, strongly binds its inhibitory receptors on immune cells (NK, T, B, monocytes/dendritic cells), inhibits the functions of these effectors, and so induces immune inhibition.
Synonyms HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.